1 / 1
Tesamorelin is a synthetic peptide drug with the structural formula ThGRF(1-44)NH₂. As a potent Growth Hormone Releasing Hormone (GHRH) analog, it simulates endogenous GHRH activity to stimulate the anterior pituitary gland to secrete Growth Hormone (GH). This process subsequently elevates insulin-like growth factor 1 (IGF-1) levels, triggering key metabolic improvements and tissue repair pathways.
Currently approved by the FDA for treating HIV-related lipodystrophy—specifically targeting abdominal visceral adipose tissue (VAT) reduction—Tesamorelin continues to be extensively studied for broader therapeutic applications across metabolic and systemic health domains.
Tesamorelin comprises a 44-amino acid peptide sequence engineered to closely mirror natural GHRH. Its physiological pathway operates through precise biological targets:
Binds directly to GHRH receptors (GHRHR) in the anterior pituitary gland, triggering the natural secretion of endogenous Growth Hormone (GH).
Elevated GH levels stimulate the liver and peripheral tissues to synthesize IGF-1, promoting lipid breakdown, tissue restoration, and cellular repair.
Acts specifically on visceral adipocytes (abdominal fat mobilization) while maintaining minimal impact on subcutaneous fat layers.
Unlike direct exogenous GH injections, Tesamorelin preserves natural pulsatile GH secretion, drastically reducing side effects such as severe fluid retention and insulin resistance.
Tesamorelin API is produced via state-of-the-art Solid Phase Peptide Synthesis (SPPS) under stringent Good Manufacturing Practice (GMP) conditions, meeting global pharmaceutical specifications:
